Rapid Induction and Maintenance of Virus-Specific CD8+ TEMRA and CD4+ TEM Cells Following Protective Vaccination Against Dengue Virus Challenge in Humans

Front Immunol. 2020 Mar 24:11:479. doi: 10.3389/fimmu.2020.00479. eCollection 2020.

Abstract

Dengue virus (DENV) is a mosquito-borne flavivirus that causes serious human disease. The current lack of an effective vaccine to simultaneously protect against the four serotypes of DENV in seronegative individuals is a major unmet medical need. Further, the immunological basis for protective immunity in the setting of DENV infection or vaccination is not fully understood. Our team has developed a live attenuated tetravalent dengue virus vaccine that provides complete protection in a human model of dengue virus challenge. The goal of this study was to define, in the context of protective human vaccination, the quality of vaccine-induced DENV-specific CD8+ and CD4+ T cells and the temporal dynamics associated with their formation and maintenance. Multifunctional, DENV-specific CD8+ and CD4+ T cells developed 8-14 days after vaccination and were maintained for at least 6 months. Virus-specific CD8 T+ cells were a mixture of effector memory T cells (TEM) and effector memory T cells re-expressing CD45RA (TEMRA), with TEM cells predominating until day 21 post-vaccination and TEMRA cells thereafter. The majority of virus-specific CD4+ T cells were TEM with a small fraction being TEMRA. The frequency of virus-specific CD8+ and CD4+ T cells were further skewed to the TEMRA phenotype following either a second dose of the tetravalent vaccine or challenge with a single serotype of DENV. Collectively, our study has defined the phenotypic profile of antiviral CD8+ and CD4+ T cells associated with protective immunity to DENV infection and the kinetics of their formation and maintenance.

Keywords: CD4; CD8; TEMRA; dengue; human challenge; memory; protective immunity; vaccine.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, N.I.H., Intramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antibodies, Neutralizing / immunology
  • Antibodies, Viral / immunology
  • Antigens, Viral / immunology
  • CD4-Positive T-Lymphocytes / chemistry
  • CD4-Positive T-Lymphocytes / immunology*
  • CD8-Positive T-Lymphocytes / chemistry
  • CD8-Positive T-Lymphocytes / immunology*
  • Clinical Trials, Phase I as Topic
  • Cytokines / analysis
  • Dengue Vaccines / immunology*
  • Dengue Virus / genetics
  • Dengue Virus / immunology*
  • Epitopes / immunology
  • Humans
  • Immunization, Secondary
  • Immunogenicity, Vaccine
  • Immunologic Memory
  • Leukocyte Common Antigens / analysis*
  • Lymphocyte Subsets / chemistry
  • Lymphocyte Subsets / immunology*
  • T-Cell Antigen Receptor Specificity*
  • Time Factors
  • Vaccination
  • Vaccines, Attenuated / immunology

Substances

  • Antibodies, Neutralizing
  • Antibodies, Viral
  • Antigens, Viral
  • Cytokines
  • Dengue Vaccines
  • Epitopes
  • Vaccines, Attenuated
  • Leukocyte Common Antigens